Ligand id: 8735

Name: avelumab

No information available.
Summary of Clinical Use
Avelumab was FDA approved in March 2017 (under the FDA's accelerated approval program) for the treament of Merkel cell carcinoma (MCC; a rare and aggressive type of skin cancer) in adults and children >12 years old. In May 2017, accelerated approval was also granted for the treatment of locally advanced or metastatic urothelial carcinoma (that has progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy). It has been granted orphan status by the EMA (December 2016) for gastric cancer. A Phase III clinical trial in non-small cell lung cancer (NSCLC) is ongoing.
Mechanism Of Action and Pharmacodynamic Effects
Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug's mechanism of action enables immune cells to detect and destroy tumour cells.